Electroacupuncture With or Without Combined Warm Needling for Tinnitus
1 other identifier
interventional
90
1 country
3
Brief Summary
This randomized controlled trial aims to evaluate the efficacy and safety of either electroacupuncture alone or combined with warm needling in reducing tinnitus loudness and improving the impairment caused by tinnitus in Hong Kong.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2022
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2022
CompletedFirst Posted
Study publicly available on registry
September 28, 2022
CompletedStudy Start
First participant enrolled
December 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 12, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 12, 2024
CompletedMay 25, 2025
May 1, 2025
1.4 years
September 18, 2022
May 21, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Tinnitus Loudness
A 0-10 numeric rating scale (NRS) will be used for rating loudness of tinnitus. Higher score indicates greater tinnitus loudness and its influence.
Baseline, Week 5, and Week 10
Secondary Outcomes (1)
Change in Tinnitus Handicap Inventory (THI)
Baseline, Week 5, and Week 10
Other Outcomes (1)
Adverse Events
Up to 10 weeks
Study Arms (3)
EA Group
EXPERIMENTALSubjects assigned to EA group will receive EA treatment twice weekly for 5 weeks.
EAWN Group
EXPERIMENTALSubjects assigned to EAWN group will receive EAWN treatment twice weekly for 5 weeks.
Waitlist Control Group
OTHERSubjects assigned to waitlist control group will not receive treatment during the 10-week waiting period after baseline assessment.
Interventions
Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min. The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side. For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.
Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min. The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side). For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11. For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17.
No treatment will be provided during the 10-week waiting period after baseline assessment.
Eligibility Criteria
You may qualify if:
- Diagnosed with subjective tinnitus;
- Male and female, age 50 to 70 years old;
- Unilateral or bilateral tinnitus for 0.5-24 months;
- Loudness of tinnitus rated 3 points or more on a 0-10 numeric rating scale (NRS) at the time of enrollment; and
- Agree to sign the informed consent form voluntarily.
You may not qualify if:
- Known disease conditions that could cause tinnitus such as Meniere's syndrome, acoustic duct diseases, and middle ear diseases;
- History of head trauma;
- Currently using cardiac pacemaker or metal implants;
- Known severe cardiac diseases, cerebrovascular diseases, renal diseases, or hematologic diseases;
- Known severe psychiatric or psychological disorder;
- Pregnant, lactation or expecting a pregnancy during the study period;
- Severe needle phobia;
- Known hypersensitive reaction after acupuncture and moxibustion treatment or an inability to cooperate with the acupuncture and moxibustion procedure;
- Incapable to understand and answer the questions of the assessors in the study; and
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lai Fun HO, PhDlead
- Chinese University of Hong Kongcollaborator
Study Sites (3)
Pok Oi Hospital-Chinese Medicine Polyclinic (Tin Shui Wai)
Hong Kong, China
Pok Oi Hospital-The Chinese University of Hong Kong Chinese Medicine Clinic cum Training ad Research Centre (Yuen Long District)
Hong Kong, China
Pok Oi Hospital-The Chinese University of Hong Kong Chinese Medicine Clinic cum Training and Research Centre (Shatin District)
Hong Kong, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yuanqi GUO
Pok Oi Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chinese Medicine Practitioner I
Study Record Dates
First Submitted
September 18, 2022
First Posted
September 28, 2022
Study Start
December 1, 2022
Primary Completion
April 12, 2024
Study Completion
April 12, 2024
Last Updated
May 25, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share